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Significance Statement 
Abnormal bone turnover of renal osteodystrophy in advanced chronic kidney disease can only be 
diagnosed using bone biopsy (gold standard). However, this is an invasive and painful procedure, 
thus rarely performed. We found that three bone biomarkers (bALP, intact PINP and TRAP5b) and 
high resolution bone imaging of distal radius can discriminate patients with low bone turnover from 
non-low bone turnover as assessed by bone histomorphometry. Hence, the biomarkers and bone 
imaging may have the potential to replace bone biopsy, particularly in discriminating patients with 
low bone turnover. They may also be useful in selecting patients for future clinical trials which aim to 
reduce their fracture risk. 
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Abstract 
Renal osteodystrophy is common in advanced chronic kidney disease (CKD) but characterization of 
bone turnover status can only be done with bone biopsy (gold standard test). We aimed to 
simultaneously test if bone biomarkers and high resolution peripheral computed tomography (HR-
pQCT) can predict bone turnover status on histomorphometry. Fasting blood samples were taken 
from 69 CKD stages 4-5 including dialysis patients and 68 controls for biomarker analysis (intact 
parathyroid hormone [iPTH], procollagen type 1 N-terminal propeptide [PINP], bone alkaline 
phosphatase [bALP], collagen type 1 cross-linked C-telopeptide [CTX] and tartrate-resistant acid 
phosphatase 5b [TRAP5b]). HR-pQCT of distal radius and tibia were performed. 43 CKD patients had 
trans-iliac bone biopsy using Jamshidi 4mm trephine for histomorphometry evaluation. All 
biomarkers were significantly higher in CKD compared to controls. BALP, intact PINP and TRAP5b had 
area under the receiver operating characteristic curve [AUC] of 0.824, 0.794 and 0.799 respectively 
to discriminate low bone turnover, significantly better than iPTH AUC of 0.606. Furthermore, radius 
HR-pQCT total volumetric bone mineral density and cortical bone volume had an AUC 0.811 and 
0.802 respectively. iPTH had AUC of 0.760 to discriminate high bone turnover, similar to other 
biomarkers in this study. In conclusion, bALP, intact PINP, TRAP5b and radius HR-pQCT can 
discriminate low from non-low bone turnover. Despite poor diagnostic accuracy for low bone 
turnover, iPTH can discriminate high bone turnover with similar accuracy to other biomarkers. 
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Introduction 
Renal osteodystrophy is characterized by abnormal bone turnover, mineralization and volume which 
can only be assessed on bone histomorphometry (gold standard test).1 However, bone biopsy is 
ŝŶǀĂƐŝǀĞĂŶĚƌĂƌĞůǇƉĞƌĨŽƌŵĞĚĚƵĞƚŽƉĂƚŝĞŶƚƐ ?ƌĞůƵĐƚĂŶĐĞŽƌůŝŵŝƚĞĚĞǆƉĞƌƚŝƐĞŝŶƚŚĞƉƌŽĐĞĚƵƌĞĂŶĚ
bone histomorphometry.  Hence, current clinical practice still relies on intact parathyroid hormone 
(iPTH) although it has been shown to have low sensitivity and specificity to assess bone turnover.2-4 
The poor diagnostic accuracy of iPTH limits its use to guide therapies that target bone mineral 
density (BMD) or bone turnover.  
Very high levels of both bone alkaline phosphatase (bALP) and iPTH are strongly predictive of high 
bone turnover in chronic kidney disease (CKD).4-10 However, bALP has better predictive ability than 
iPTH for low bone turnover.4-6, 9 There are other bone turnover biomarkers which are directly 
released during the process of bone resorption (e.g. collagen type 1 cross-linked C-telopeptide [CTX] 
and tartrate-resistant acid phosphatase 5b [TRAP5b]) and bone formation (e.g. procollagen type 1 N-
terminal propeptide [PINP]), thus are potentially more accurate in assessing bone turnover in CKD. 
The changes in BMD and microarchitecture associated with high or low bone turnover cannot be 
adequately assessed by dual energy X-ray absorptiometry (DXA) which is a 2-dimensional imaging 
technique.11 However, high-resolution peripheral quantitative computed tomography (HR-pQCT) can 
detect microarchitectural changes in both the cortical and trabecular bone compartments. Previous 
studies using HR-pQCT showed that CKD patients had thinner cortical bone and lower trabecular 
bone volume compared to healthy controls.12-14   
The emergence of bone biomarkers and HR-pQCT offer the possibility of replacing bone biopsy, but 
their diagnostic accuracy for predicting bone turnover in advanced CKD is unknown. We aimed to 
simultaneously test if Biomarkers and HR-pQCT can identify advanced CKD patients with low and 
high bone turnover as shown on histomorphometry. We also tested whether these non-invasive 
tests have better diagnostic accuracy than iPTH. 
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Methods 
Study design and population 
This was a cross-sectional study in CKD stages 4-5 (including dialysis) patients, aged 30-80 years old. 
The exclusion criteria included fracture/orthopaedic surgery in the preceding six months; 
started/changed the dose of phosphate binders, vitamin D or calcimimetics within four weeks of 
study entry; and received anti-resorptive, anabolic agent or systemic glucocorticoid in the preceding 
six months. All patients attending our Nephrology centre who fulfilled the inclusion and exclusion 
criteria were invited to take part in the study. We also recruited age- and gender-matched controls 
with estimated glomerular filtration rate (eGFR) ш ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ ? ?dŚĞĞǆĐůƵƐŝŽŶĐƌŝƚĞƌŝĂǁĞƌĞ
similar to CKD group and we also excluded participants with known osteoporosis. The study adhered 
to the Declaration of Helsinki and was approved by the South Yorkshire Research Ethics Committee. 
All participants gave written informed consent. All samples and imaging studies were obtained 
purely for research and summarised below. Complete methods is provided in the supplementary 
material.  
 Bone biomarkers 
Fasting morning blood samples were taken, stored at -800C and analysed at the end of the study. For 
haemodialysis patients, blood samples were taken on the day after their haemodialysis session. We 
measured serum iPTH, bALP, intact PINP, CTX, TRAP5b and 25-hydroxyvitamin D using the IDS-iSYS 
auto-analyser (Immunodiagnostic Systems, United Kingdom). Total PINP was measured using the 
Cobas e411 automated immunoassay (Roche Diagnostics, Germany). We measured fasting serum 
calcium, phosphate, total alkaline phosphatase (total ALP), and creatinine on Roche Cobas c701/702 
analyser (Roche Diagnostics, England) on the same day as sample collection. eGFR was calculated 
using Modification of Diet in Renal Disease equation. 
Bone imaging 
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HR-pQCT of the distal radius and tibia were performed using XtremeCT (Scanco Medical AG, 
Switzerland) using a standard protocol. The images were analysed with standard software (Scanco 
Medical AG, version 6.0) for volumetric BMD (mg/cm3) and microarchitectural parameters. The 
extended cortical measurement was also performed.  
DXA of the lumbar spine (L1-4), hip and forearm were performed using Hologic Discovery A 
densitometer (Hologic Inc, USA).  Mean areal BMD (g/cm2) was calculated using Hologic APEX 
software (version 3.4.2).  
Trans-iliac bone biopsy and histomorphometry 
Bone biopsy was only performed in CKD patients using tetracycline bone labelling. A trans-iliac bone 
biopsy was performed under local anaesthetic using an 8-gauge Jamshidi 4mm trephine and needle. 
The samples were analysed using the Bioquant Osteo histomorphometry system (Bioquant Image 
Analysis Corporation) which uses standardised nomenclature.15 The samples fulfilled the 
histomorphometry minimum acceptable total section area in the standard analysis region of 
30mm2.16 All histomorphometry analysis was performed by a single operator (OG) and normal bone 
turnover was defined as bone formation rate/ bone surface (BFR/BS) of 18-38 um3/um2/year.17 
Statistical analysis 
Descriptive statistics were presented as mean (standard deviation [SD]) and median (interquartile 
range [IQR]). We used Student t-test, Mann-Whitney U test and chi-squared test to compare the 
characteristics of CKD and controls, and Spearman rank analysis to identify the associations between 
variables.  
We selected 43 controls who were age- and gender-matched to the 43 CKD patients with bone 
histomorphometry to obtain HR-pQCT Z-scores. HR-pQCT Z-scores were used in order to control for 
the age and gender effects on bone microarchitecture and BMD. The Z-scores were calculated using 
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the formula: (HR-pQCT CKD measurement  ? mean of control group)/(SD of control group).  DXA 
BMD Z-scores were obtained from the Hologic software. 
For receiver operating characteristic (ROC) analysis, CKD patients were grouped into Low/Non-Low 
and High/Non-High bone turnover categories based on bone turnover on histomorphometry 
(BFR/BS). The proportions of low and high bone turnover in this study were used as prevalence of 
the disease. We classified area under the ROC curve (AUC) of 0.6-0.7 as poor, 0.7-0.8 as fair, 0.8-0.9 
as good and 0.9-1.0 as excellent diagnostic accuracy. Combining variables for ROC analysis was 
performed using regression analysis.  
We used p<0.05 to indicate statistical significance. All statistical analysis were performed using IBM 
SPSS Statistics 22 and MedCalc v16.8.4.  
 
Results 
Participants and the bone turnover on histomorphometry. 
The demographics of 69 advanced CKD stages 4-5 (including dialysis) patients and 68 age- and 
gender-matched control participants are shown in Table 1. There were 44 pre-dialysis CKD patients 
with median (IQR) eGFR of 13 (11-16) ml/min/1.73m2 and 25 dialysis patients (haemodialysis and 
peritoneal dialysis). Median (IQR) eGFR for controls was 81 (72 to >90) ml/min/1.73m2.  
49 bone biopsies were performed but only 43 samples were adequate for histomorphometry 
analysis. Amongst these 43 patients, 28 (65%) were pre-dialysis CKD, mean (SD) age was 59 (12) 
years, 77% were male, 26% had diabetes, and 26% had previous fragility fracture. Their current 
medications are shown in Table 2 but none were taking calcimimetics. Based on bone formation 
rate/bone surface (BFR/BS) on histomorphometry, 26% of patients had low, 34% had normal and 
40% had high bone turnover (Table 2).  
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Biomarkers and imaging in CKD and controls. 
CKD patients had significantly higher biomarker levels compared to controls (Table 1). On HR-pQCT, 
CKD patients had lower volumetric BMD, and lower trabecular thickness and trabecular bone 
volume at the distal radius and distal tibia compared to controls (Table 1). Additionally, CKD patients 
had a thinner cortical bone at the tibia. Figure 1 shows examples of 3-dimensional reconstruction of 
HR-pQCT images at both sites in this study. 
Areal BMD Z-score by DXA at the forearm and total hip were also lower in CKD compared to controls 
(Table 1). 59% of the CKD group had osteopaenia (T score -1.0 to -2.5), and 25% had osteoporosis (T 
score<-2.5) as assessed by BMD at the three sites. In the control group, 51% had osteopaenia, and 
12% had osteoporosis.   
 
Relationship between bone turnover on histomorphometry and biomarkers and imaging in CKD 
In 43 CKD patients with bone histomorphometry data, all biomarkers were significantly correlated 
with each other (Supplementary Table 1). iPTH was positively associated with bone turnover 
[BFR/BS] (rho= 0.42, p<0.01) but the other biomarkers showed higher correlations with bone 
turnover (Figure 2). There were significant differences for all the biomarkers between low, normal 
and high bone turnover categories (Table 2). 
Bone turnover on histomorphometry was negatively associated with radius Z-scores for BMD and 
microarchitecture (Figure 3) but no significant associations were found with tibia HR-pQCT Z-scores. 
Differences were only significant for radius HR-pQCT total BMD and cortical bone volume (p<0.05) 
between the three bone turnover categories (Table 2). On DXA, only the forearm BMD Z-score was 
significantly associated with bone turnover (rho= -0.307, p<0.05). No significant differences were 
found for DXA BMD Z-scores between the bone turnover categories (Table 2). 
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Diagnostic accuracy of biomarkers and imaging for low bone turnover 
In ROC analysis for discriminating low from non-low bone turnover, AUC for bALP was 0.824, intact 
PINP was 0.794 and TRAP5b were 0.799 (Table 3). These AUCs were significantly better (p<0.05) 
than AUC for iPTH which was 0.606 (Figure 4a). Combining biomarkers did not improve the AUC. 
Radius HR-pQCT Z-scores for total BMD and cortical bone volume had AUC of 0.811 and 0.802 
respectively for discriminating low bone turnover (Figure 4b, Table 3). However, these AUCs were 
not significantly better than iPTH AUC. Tibia HR-pQCT Z-scores only had AUCs ч0.70. All three sites 
DXA BMD Z-scores also had non-significant AUCs (Supplementary Table 2). Combining bALP and 
radius total BMD Z-score did not improve the AUC (Table 3). 
 
Diagnostic accuracy of biomarkers and imaging for high bone turnover 
In ROC analysis for discriminating high from non-high bone turnover, iPTH had an AUC of 0.76 which 
was similar to AUCs for the other biomarkers (Table 4). Combining biomarkers did not improve the 
AUC. All bone imaging parameters also had non-significant AUCs (Supplementary Table 2 & 3).  
 
Discussion 
This is the first study to simultaneously compare biomarkers and HR-pQCT to bone 
histomorphometry to determine their diagnostic accuracy in discriminating bone turnover status in 
advanced CKD patients. BALP and radius HR-pQCT can discriminate low bone turnover, with their 
AUCs being >0.80. We also found that iPTH, all the biomarkers and bone imaging had similarly 
suboptimal diagnostic accuracy for discriminating high bone turnover. 
BALP, intact PINP and TRAP5b can discriminate patients with low bone turnover better than iPTH, 
most likely because they do not accumulate in advanced CKD.18, 19 Secondary hyperparathyroidism is 
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a common complication in advanced CKD and has a major role in CKD mineral bone disorder (CKD-
MBD).1 iPTH is a poor diagnostic test to discriminate low bone turnover in advanced CKD patients, 
partly due to the assay used. A second generation iPTH assay measures the whole (1-84) PTH 
molecule and the (7-84) PTH fragment. The fragment accumulates in CKD and has an antagonistic 
effect on bone turnover.20 Despite those limitations, iPTH can still discriminate high bone turnover 
with similar accuracy as other biomarkers used in this study. iPTH has 90% positive predictive value 
(PPV) for high bone turnover which is consistent with previous studies.6, 7, 10 The optimal cut off value 
for discriminating high bone turnover in this study is five times the upper limit of normal, whereas 
KDIGO CKD-MBD guideline recommends that iPTH level is maintained 2-9 times the upper limit of 
normal in dialysis patients.1 The number of dialysis patients in our study was too small for further 
analysis to make a comparison. 
In this study, bALP had AUC>0.80 and has better diagnostic accuracy for low bone turnover than 
iPTH which are consistent with previous studies. 5, 6, 8, 9 BALP and other biomarkers in this study had 
consistently low PPV but high negative predictive value for the optimal threshold (criterion) for low 
bone turnover. We also found that bALP only has 69% PPV for discriminating high bone turnover 
whereas previous studies found >90% PPV.6, 7, 10  
Sprague et al. recently published diagnostic accuracy of biomarkers in predicting bone turnover in 
492 dialysis patients from four countries.4 They also showed that iPTH had similar diagnostic 
accuracy to bALP and PINP in predicting high bone turnover. They found that bALP and iPTH had the 
highest diagnostic accuracy for low bone turnover but we found that iPTH to be a poor diagnostic 
test for low bone turnover. They also found that combining iPTH and bALP improved the 
discrimination of both low and high bone turnover but this is not the case in our study. There are 
differences between the study and ours; firstly, we included pre-dialysis and dialysis patients which 
may account for the different proportion of patients with low bone turnover. Although our sample 
size was smaller, the proportion of patients with low bone turnover was similar to other studies.5, 9 
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In contrast, Sprague et al. reported that around 60% of patients had low bone turnover but most of 
their biopsies were performed for clinical indication whereas ours were collected purely for 
research. Our histomorphometry analysis was performed by a single operator to reduce intra-
observer variability whereas Sprague et al. had bone histomorphometry analysed in several centres 
with different ranges of bone turnover defined as normal. The assays used for iPTH and bALP were 
also different from ours and Sprague et al used total PINP whereas we evaluated total and intact 
PINP separately.  
PINP is cleaved off from type 1 collagen during bone formation process. Total PINP assay measures 
the trimeric propeptide and its monomeric fragments, whilst the intact PINP assay only measures 
the trimeric propeptide.19 The trimeric propeptide is cleared from circulation by liver endothelial 
cells,21 whereas the monomeric fragments are cleared by the kidneys, hence the fragments 
accumulate in advanced CKD.19 We have shown that in advanced CKD, (1) only intact PINP can 
discriminate low bone turnover better than iPTH and (2) both have suboptimal diagnostic accuracy 
for high bone turnover. Although total PINP is often used in the field of osteoporosis, we do not 
recommend its use to assess bone turnover in advanced CKD. 
Biomarker profile in dialysis patients may differ from that in non-dialysis CKD even with similar bone 
turnover status because biomarkers, such as CTX, may be dialysed.22 Hence, our haemodialysis 
patients had blood sample taken the day after a dialysis session but we did not assess residual renal 
function. These issues may have introduced bias in our study. However, the number of pre-dialysis 
patients was small with <10 patients each in the low and high bone turnover categories which makes 
further analysis in this subgroup questionable.  
CKD patients in our study had lower BMD on HR-pQCT compared to controls which is mostly due to 
cortical bone impairment. Additionally, CKD patients also had thinner cortical bone at the tibia. 
Previous studies also found that CKD had lower BMD on HR-pQCT compared to controls due to both 
trabecular and cortical bone impairment.12-14  However, we did not match our control participants ?
12 
 
BMD to CKD patients and we excluded participants with known osteoporosis which may have 
introduced bias.  
We found that radius BMD and microarchitecture were negatively associated with bone turnover in 
advanced CKD. Negri et al. showed similar trend on HR-pQCT in female dialysis patients but they 
used biomarkers as measures of bone turnover rather than bone histomorphometry.14 We also 
found that normal and high bone turnover CKD patients had significantly lower radius BMD 
compared to those with low bone turnover, mostly due to lower cortical bone volume. Gerakis et al. 
described similar finding using DXA in haemodialysis patients who had a bone biopsy.23 We did not 
find any difference in DXA BMD between bone turnover categories. Importantly, DXA is unable to 
discriminate bone turnover status in advanced CKD. 
Distal radius HR-pQCT can discriminate low bone turnover from non-low bone turnover patients in 
this study. However, it is important to recognise that the effects of bone turnover on 
microarchitecture are dynamic whereas HR-pQCT is a static test. Thus the cross-sectional use of HR-
pQCT is perhaps more appropriate in assessing bone volume (static measurement) rather than bone 
turnover (dynamic measurement).24 Nevertheless, the use of bone imaging could be complementary 
to biomarkers in discriminating bone turnover status and deciding treatment decisions, for example, 
in osteoporotic CKD. 
We included pre-dialysis and dialysis CKD patients and we assessed bone turnover using the gold 
standard bone biopsy but there were several limitations to our study. This was a single centre 
observational study with a small number of participants. However, the proportion of patients with 
low/high bone turnover was similar to previous studies, and we had a broad range of bone turnover 
which is important in assessing diagnostic test accuracy. We were unable to assess pre-dialysis and 
dialysis patients separately. Hence, our results must be interpreted in the context of CKD stages 4-5 
and dialysis.  
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In conclusion, bALP, intact PINP, TRAP5b and radius HR-pQCT were able to discriminate low bone 
turnover in advanced CKD patients. Despite poor diagnostic accuracy for low bone turnover, iPTH 
can discriminate high bone turnover with similar accuracy to other biomarkers in this study. In 
clinical practice, iPTH and bALP remain the diagnostic tests of choice to discriminate high and low 
bone turnover. However, we believe that all four biomarkers and radius HR-pQCT can potentially be 
used for patient selection in clinical trials in advanced CKD as we continue to search for bone-specific 
treatment to reduce fracture risk in this population. 
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Table 1: Demographics, biomarkers and imaging parameters in CKD patients and control 
participants. 
Variables CKD (N=69) Control (N=68) p values 
Age, years 62 (12) 62 (12)  
Male, N 53 53  
BMI (kg/m2) 27 (4.1) 28 (4.3) 0.3 
Diabetes 28% 0% <0.001 
Previous fragility fracture 22% 7% <0.05 
    
Biomarkers 
   
iPTH (pg/mL) 188 (121 ± 280) 32 (27 ± 45) <0.001 
Intact PINP (ng/mL) 67.5 (42.8 ± 107.7) 38.5 (31.8 ± 55.3) <0.001 
Total PINP (ng/mL) 125 (72.8 ± 237.2) 41.4 (33.7 ± 56.7) <0.001 
bALP (µg/L) 22.3 (16.6 ± 33.3) 17 (12.9 ± 20.2) <0.001 
tALP (IU/L) 88 (73 ± 126) 65.5 (55.3 ± 78) <0.001 
CTX (ng/mL) 1.49 (0.76 ± 2.39) 0.27 (0.19 ± 0.5) <0.001 
TRAP5b (U/L) 4.9 (3.2 ± 6.9) 3.8 (3.3 ± 4.5) 0.001 
Adjusted calcium (mmol/L) 2.28 (0.15) 2.28 (0.07) 0.9 
Phosphate (mmol/L) 1.53 (0.3) 1.06 (0.15) <0.001 
25-hydroxyvitamin D (ng/mL) 22.9 (9.4) 23.9 (7.0) 0.5 
    
HRpQCT distal radius 
   
Total vBMD (mg/cm3) 266.2 (75.56) 308.47 (74.2) 0.003 
Cortical vBMD (mg/cm3) 782.58 (110.66) 821.04 (88.7) 0.04 
Trabecular vBMD (mg/cm3) 156.69 (46.17) 184.6 (41.42) 0.001 
Cortical thickness (mm) 0.61 (0.27) 0.71 (0.26) 0.06 
Cortical porosity (%) 3.0 (2.3 ± 4.2) 3.2 (2.0 ± 3.8) 0.4 
Cortical BV/TV (%) 90.0 (85.4 ± 92.1) 90.7 (88.6 ± 93.4) 0.1 
Trabecular thickness (mm) 0.064 (0.012) 0.073 (0.013) <0.001 
Trabecular number (1/mm) 2.01 (0.363) 2.11 (0.296) 0.14 
Trabecular separation (mm) 0.434 (0.371 ± 0.496) 0.4 (0.349 ± 0.443) 0.06 
Trabecular BV/TV (%) 13.1 (3.8) 15.4 (3.5) 0.001 
   
 
HRpQCT distal tibia 
  
 
Total vBMD (mg/cm3) 276.99 (63.67) 314.97 (61.2) 0.001 
Cortical vBMD (mg/cm3) 819.85 (88.67) 858.7 (67.89) 0.005 
Trabecular vBMD (mg/cm3) 172.12 (41.06) 189.99 (41.12) 0.01 
Cortical thickness (mm) 1.05 (0.36) 1.25 (0.35) 0.001 
Cortical porosity (%) 7.1 (5.7 ± 10.4) 6.8 (4.7 ± 10.3) 0.2 
Cortical BV/TV (%) 86.2 (6.0) 88.1 (4.9) 0.05 
Trabecular thickness (mm) 0.075 (0.014) 0.081 (0.013) 0.01 
Trabecular number (1/mm) 1.92 (0.35) 1.97 (0.4) 0.4 
Trabecular separation (mm) 0.444 (0.395 ± 0.522) 0.425 (0.359 ± 0.523) 0.2 
Trabecular BV/TV (%) 14.3 (3.4) 15.8 (3.4) 0.01 
   
 
DXA BMD Z-score 
  
 
Forearm -0.4 (1.5) 0.2 (1.4) 0.02 
Total hip -0.2 (1.0) 0.6 (1.1) <0.001 
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Lumbar spine 0.4 (1.7) 0.5 (1.6) 0.7 
 
Data presented as mean (standard deviation) for normal distribution variables and median (inter-
quartile range) for non-normal distribution variables. Group differences were tested using 
independent t-test for normal distribution variables, Mann-Whitney U test for non-normal 
distribution variables and chi squared test for categorical variables.  
Abbreviations: eGFR; estimated glomerular filtration rate; BMI, body mass index; iPTH, intact 
parathyroid hormone; PINP, procollagen type 1 N-terminal propeptide; bALP, bone alkaline 
phosphatase; tALP, total alkaline phosphatase CTX, collagen type 1 cross-linked C-telopeptide; 
TRAP5b, tartrate-resistant acid phosphatase 5b; HR-pQCT, high resolution peripheral quantitative 
computed tomography; vBMD, volumetric bone mineral density; BV/TV, bone volume/tissue 
volume; DXA, dual energy X-ray absorptiometry; BMD, bone mineral density. 
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Table 2: Biomarkers and imaging parameters for low, normal and high bone turnover categories in 
advanced chronic kidney disease patients (N=43). 
Variables Low (N=11) Normal (N=15) High (N=17) p value 
BFR/BS (um3/um2/day) 13.8 (3.6 ± 15.5) 27.5 (22.5 ± 32.2) 67.4 (46.5 ± 112.5) <0.001 
    
 
Medications 
   
 
Vitamin D 45% 13% 47%  
Calcium based phosphate binder 9% 20% 41%  
Non-Calcium based phosphate 
binder 0% 7% 6%  
    
 
Biomarkers     
iPTH (pg/mL) 172 (119 ± 292) 172 (86 ± 194) 347 (161 ± 381) <0.05 
Intact PINP (ng/mL) 44.1 (29.2 -68.4) 81.1 (54.3 ± 92.4) 107.9 (63.5 ± 182) <0.005 
Total PINP (ng/mL) 76.3 (51.7 ± 159.3) 127.3 (68.4 ± 221.7) 214 (110.6 ± 403) <0.05 
bALP (µg/L) 17.7 (5.6) 25.9 (8.7) 34.4 (13.3) <0.005 
tALP (IU/L) 82 (53 ± 86) 94 (82 ± 127) 115 (82 ± 156) <0.05 
CTX (ng/mL) 1.01 (0.68) 1.46 (0.67) 2.65 (1.68) <0.005 
TRAP5b (U/L) 3.2 (2.9 ± 4.3) 5.2 (3.2 ± 7.4 ) 5.8 (4.8 ± 8.5) <0.05 
Adjusted calcium (mmol/L) 2.27 (2.22 ± 2.33) 2.32 (2.26 ± 2.35) 2.24 (2.14 ± 2.40) 0.6 
Phosphate (mmol/L) 1.48 (1.30 ± 1.77) 1.61 (1.43 ± 1.83) 1.30 (1.25 ± 1.55) 0.1 
25-hydroxyvitamin D (ng/mL) 23 (9.9) 23.7 (8.2) 22.6 (10.3) 0.95 
     
HR-pQCT radius Z-score     
Total vBMD -0.11 (0.63) -1.06 (0.66) -0.97 (1.08) <0.05 
Cortical vBMD 0.49 (-0.47  to 0.9) -0.63 (-1.4 to -0.14) -0.84 (-1.67 to 0.15) 0.09 
Trabecular vBMD -0.31 (0.83) -1.03 (0.57) -1.11 (1.31) 0.16 
Cortical thickness 0.07 (0.8) -0.76 (0.82) -0.64 (0.98) 0.1 
Cortical porosity -0.51 (-0.95 to -0.02) -0.12 (-0.94 to 1.58) 0.10 (-0.47 to 0.90) 0.15 
Cortical BV/TV 0.72 (-0.08 to 0.97) -0.2 (-1.48 to 0.27) -0.23 (-1.46 to 0.27) <0.05 
Trabecular thickness -0.43 (-0.82 to -0.18) -1.14 (-1.57 to -0.79) -1.21 (-1.77 to 0.11) 0.07 
Trabecular number -0.03 (1.01) -0.11 (0.84) -0.66 (1.58) 0.39 
Trabecular separation -0.13 (-0.5 to 0.71) 0.30 (-0.39 to 0.55) 0.59 (-0.50 to 1.18) 0.5 
Trabecular BV/TV -0.30 (0.82) -1.01 (0.57) -1.09 (1.31) 0.17 
     
HR-pQCT tibia Z-score     
Total vBMD -0.34 (0.91) -1.05 (0.90) -0.92 (1.13) 0.21 
Cortical vBMD 0.26 (-0.93 to 0.44) -0.60 (-2.0 to 0.31) -0.21 (-2.0 to 0.13) 0.13 
Trabecular vBMD -0.48 (0.92) -0.63 (0.88) -0.70 (1.11) 0.86 
Cortical thickness -0.18 (0.92) -1.1 (0.86) -0.86 (1.16) 0.1 
Cortical porosity -0.31 (0.52) 0.43 (1.26) 0.31 (1.17) 0.23 
Cortical BV/TV 0.36 (-0.15 to 0.73) -0.43 (-1.82 to 0.70) 0.14 (-2.12 to 0.37) 0.17 
Trabecular thickness -0.70 (-0.87 to 0.23) -0.93 (-1.62 to 0.21) -0.78 (-1.66 to 0.14) 0.44 
Trabecular number -0.31 (1.23) -0.03 (0.76) -0.07 (0.92) 0.74 
Trabecular separation 0.56 (-0.75 to 0.84) -0.09 (-0.30 to 0.55) -0.04 (-0.44 to 0.52) 0.66 
Trabecular BV/TV -0.46 (0.91) -0.60 (0.88) -0.67 (1.10) 0.86 
     
DXA BMD Z-score     
Forearm -0.24 (0.88) -0.31 (0.99) -0.94 (1.33) 0.18 
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Total hip -0.07 (0.76) -0.35 (0.96) -0.38 (1.05) 0.68 
Lumbar spine -0.10 (-0.5 to 0.6) 0.2 (-0.8 to 1.0) 0 (-0.8 to 1.3) 0.86 
 
Data is presented as mean (standard deviation) for normal distribution variables or median 
(interquartile range) for non-normal distribution variables. Group differences were tested using one-
way ANOVA or Kruskal-Wallis test depending on the distribution of the variables. 
Abbreviations: BFR/BS, bone formation rate/bone surface; eGFR; estimated glomerular filtration 
rate; BMI, body mass index; iPTH, intact parathyroid hormone; PINP, procollagen type 1 N-terminal 
propetide; bALP, bone alkaline phospahatse; tALP, total alkaline phosphatase; CTX, collagen type 1 
cross-linked C-telopeptide; TRAP5b, tartrate-resistant acid phosphatase 5b; HR-pQCT, high 
resolution peripheral quantitative computed tomography; vBMD, volumetric bone mineral density; 
BV/TV, bone volume/tissue volume; DXA, dual energy X-ray absorptiometry; BMD, bone mineral 
density. 
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Table 3: Diagnostic accuracy of biomarkers and radius HR-pQCT for identifying patients with low 
bone turnover 
Variables AUC (95% CI) Criterion Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
Biomarkers 
iPTH 0.563 (0.401 to 0.715) SJP/ 70 53 32 85 
Intact PINP 0.794 (0.641 to 0.903) QJP/ 80 75 50 92 
Total PINP 0.719 (0.557 to 0.848) QJP/ 80 68 44 91 
bALP 0.824 (0.671 to 0.926) J/ 89 77 53 96 
tALP 0.753 (0.598 to 0.871) ,8/ 91 63 46 95 
CTX 0.766 (0.610 to 0.882) QJP/ 60 84 55 87 
TRAP5b 0.799 (0.643 to 0.909) 8/ 89 71 47 96 
 
Radius HR-pQCT Z-score 
Total vBMD 0.811 (0.646 ± 0.922) >-1.0 100 59 45 100 
Cortical BV/TV 0.802 (0.636 ± 0.916) > -0.2 89 63 44 94 
 
Combined variables 
bALP & radius total 
vBMD Z-score 0.797 (0.621 ± 0.916) Not available 100 58 39 100 
 
Abbreviations: HR-pQCT, high resolution peripheral quantitative computed tomography; AUC, area 
under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive 
value; NPV, negative predictive value; iPTH, intact parathyroid hormone; PINP, procollagen type 1 N-
terminal propeptide ; bALP, bone alkaline phosphatase; tALP, total alkaline phosphatase; CTX, 
collagen type 1 cross-linked C-telopeptide; TRAP5b, tartrate-resistant acid phosphatase 5b; vBMD, 
volumetric bone mineral density; BV/TV, bone volume/tissue volume.  
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Table 4: Diagnostic accuracy of biomarkers for identifying patients with high bone turnover. 
Biomarkers AUC (95% CI) Criterion Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
iPTH 0.760 (0.603 to 0.878) >327 pg/mL 53 96 90 75 
Intact PINP 0.765 (0.609 to 0.882) >107 ng/mL 53 92 82 74 
Total PINP 0.725 (0.563 to 0.853) >142ng/mL 75 68 60 81 
bALP 0.750 (0.588 to 0.873) >31 µg/L 56 83 69 74 
tALP 0.670 (0.510 to 0.805) >102 IU/L 65 73 61 76 
CTX 0.762 (0.606 to 0.880) >2.39 ng/mL 53 96 90 75 
TRAP5b 0.710 (0.545 to 0.842) >4.6 U/L 81 58 57 82 
 
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; 
PPV, positive predictive value; NPV, negative predictive value; iPTH, intact parathyroid hormone; 
PINP, procollagen type 1 N-terminal propeptide ; bALP, bone alkaline phosphatase; tALP, total 
alkaline phosphatase; CTX, collagen type 1 cross-linked C-telopeptide; TRAP5b, tartrate-resistant 
acid phosphatase 5b. 
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Figure legends 
Figure 1: Examples of HR-pQCT 3-dimensional images of distal radius and distal tibia from a control 
participant and a CKD patient in this study. This CKD patient demonstrated trabecular bone 
impairment whereas the control participant had normal bone microarchitecture. 
 
Figure 2: All biomarkers showed positive correlations with bone turnover on histomorphometry 
(N=43). 
Abbreviations: BFR/BS, bone formation rate/bone surface; PINP, procollagen type 1 N-terminal 
propeptide; ALP, alkaline phosphatase; CTX, collagen type 1 cross-linked C-telopeptide; TRAP5b, 
tartrate-resistant acid phosphatase 5b. 
 
Figure 3: Distal radius HR-pQCT parameters showed negative correlations with bone turnover on 
histomorphometry (N=43). 
Abbreviations: BFR/BS, bone formation rate/bone surface; HR-pQCT, high resolution peripheral 
quantitative computed tomography; vBMD, volumetric bone mineral density; BV/TV, bone 
volume/tissue volume. 
 
Figure 4: Biomarkers and distal radius HR-pQCT parameters can discriminate CKD patients with low 
bone turnover. Receiver operating characteristic curves show that the biomarkers bALP, intact PINP 
and TRAP5b (panel A) performed significantly better than iPTH in discriminating patients with low 
bone turnover. Distal radius HR-pQCT parameters (panel B) were not significantly better than iPTH 
despite area under the curves being >0.80. 
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Abbreviations: iPTH, intact parathyroid hormone; bALP, bone alkaline phosphatase; PINP, 
procollagen type 1 N-terminal propeptide; TRAP5b, tartrate-resistant acid phosphatase 5b; HR-
pQCT, high resolution peripheral quantitative computed tomography; vBMD, volumetric bone 
mineral density; BV/TV, bone volume/tissue volume. 
 
 
